Neurogene Inc. Asset Acquisition Consideration Transferred Contingent Consideration
Neurogene Inc. (NGNE) reported Asset Acquisition Consideration Transferred Contingent Consideration of $400.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes
us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration · last filed 2026-08-11
- Neurogene Inc. asset acquisition consideration transferred contingent consideration for the quarter ending 2026-06-30 was $0.00.
- Neurogene Inc. asset acquisition consideration transferred contingent consideration for the quarter ending 2026-03-31 was $400.00K, a 66.67% decline year-over-year.
- Neurogene Inc. asset acquisition consideration transferred contingent consideration for the quarter ending 2025-12-31 was $0.00.
- Neurogene Inc. asset acquisition consideration transferred contingent consideration for the quarter ending 2025-09-30 was -$500.00K.
- Neurogene Inc. asset acquisition consideration transferred contingent consideration for fiscal 2025 was $700.00K, a 41.67% decline from fiscal 2024.
- Neurogene Inc. asset acquisition consideration transferred contingent consideration for fiscal 2024 was $1.20M, a 7.69% decline from fiscal 2023.
- Neurogene Inc. asset acquisition consideration transferred contingent consideration for fiscal 2023 was $1.30M.
| Period end | Asset Acquisition Consideration Transferred Contingent Consideration 3 month | Asset Acquisition Consideration Transferred Contingent Consideration 6 month | Asset Acquisition Consideration Transferred Contingent Consideration 9 month | Asset Acquisition Consideration Transferred Contingent Consideration 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $400.00K 10-Q · filed 2026-08-11 | $400.00K derived: sum of 3 quarters · filed 2026-08-11 | -$100.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $400.00K 10-Q · filed 2026-05-12 | $400.00K derived: sum of 2 quarters · filed 2026-05-12 | -$100.00K derived: sum of 3 quarters · filed 2026-05-12 | -$100.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$500.00K derived: sum of 2 quarters · filed 2026-03-24 | -$500.00K derived: sum of 3 quarters · filed 2026-03-24 | $700.00K 10-K · filed 2026-03-24 |
| 2025-09-30 | -$500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$500.00K derived: sum of 2 quarters · filed 2025-11-13 | $700.00K 10-Q · filed 2025-11-13 | $700.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.20M 10-Q · filed 2025-08-11 | $1.20M derived: sum of 3 quarters · filed 2025-08-11 | $1.10M derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | $1.20M 10-Q · filed 2025-05-09 | $1.20M derived: sum of 2 quarters · filed 2025-05-09 | $1.10M derived: sum of 3 quarters · filed 2025-05-09 | $1.10M derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$100.00K derived: sum of 2 quarters · filed 2025-03-24 | -$100.00K derived: sum of 3 quarters · filed 2025-03-24 | $1.20M 10-K · filed 2025-03-24 |
| 2024-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | -$100.00K derived: sum of 2 quarters · filed 2024-11-18 | $1.20M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $1.30M 10-Q · filed 2024-08-09 | ||
| 2024-03-31 | $1.30M 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | $1.30M 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |